Prasterone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Prasterone: Heparin cofactor 2 deficiency
One-Sentence Summary
Prasterone (DHEA) is a steroid hormone precursor, originally associated with systemic lupus erythematosus and with painful intercourse (dyspareunia) linked to vulvar and vaginal atrophy. The TxGNN model predicts it may be effective for heparin cofactor 2 deficiency, but there are currently 0 clinical trials and 0 publications supporting this prediction. It rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Heparin cofactor 2 deficiency |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Prasterone is the pharmaceutical form of dehydroepiandrosterone (DHEA), a steroid hormone precursor. It is approved in the US for moderate to severe dyspareunia due to vulvar and vaginal atrophy. Pharmacology data also list the glycine receptor as one of its targets.
Heparin cofactor II deficiency is a rare inherited disorder of a serpin (SERPIND1) involved in blood clotting regulation. No documented mechanistic connection exists between prasterone and this protein. The high score (0.9999) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
The other top predictions are mostly inherited clotting disorders (factor 5 excess, antithrombin deficiency type 2, thrombophilia, protein S deficiency). Hormonal agents can alter thrombotic risk, so these predictions call for caution rather than enthusiasm. A pro-thrombotic signal would be a safety concern, not a benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02493500 | INTRAROSA | Not specified | Not specified |
Safety Considerations
Drug Interactions / Pharmacology:
- One pharmacology record lists the glycine receptor (all subtypes) as a target of DHEA. This is a target association, not a drug-drug interaction with a clinical severity rating.
Additional note from the predictions:
- Hormonal therapies can alter thrombotic risk. This is relevant because the top predicted indications are coagulation disorders.
For full warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. There are no clinical trials or publications, no known mechanism linking prasterone to heparin cofactor II deficiency, and a plausible thrombotic safety concern for hormonal agents in clotting disorders. The same holds for the other nine predicted indications, all at evidence level L5.
To proceed, the following is needed:
- Package insert warnings and contraindications from Health Canada (currently missing, and a blocking gap for safety screening)
- Mechanism of action data for prasterone (for example from DrugBank)
- Any preclinical or clinical evidence linking DHEA to SERPIND1/heparin cofactor II function
- Review of thrombotic risk with hormonal therapy in patients with inherited coagulation disorders
- Dosage form, route and approved indication details for the Canadian product, to assess route compatibility
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.